Clinical Trial Matcher

Condition

Type 1 Diabetes Mellitus recruiting studies and washout check

575 studies matched on ClinicalTrials.gov for the query below. Retrieved September 28, 2026. This page does not say who can enroll.

Query

Type 1 Diabetes Mellitus OR Type 1 Diabetes OR Diabetes Mellitus Type 1

Names the matcher also recognizes: Type 1 Diabetes, T1D, Diabetes Mellitus Type 1. Abbreviations shorter than five letters stay off the query so a string such as MS does not pull unrelated records. Status filter: recruiting or not yet recruiting. The same names are how a personalized search starts. Washout timing still needs the treatment end date you enter on the search form. Read how matching works before treating any line below as a fit.

Studies in this retrieval

  1. NCT06860516

    HLA Demographics Study in Adults With Type 1 Diabetes

    Recruiting · Not specified · registry updated 2026-08-28

    This is a study to evaluate the HLA-DRB1\*04:01 genotype in adults that have been diagnosed with type 1 diabetes

  2. NCT06630585

    GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

    Recruiting · Phase 3 · registry updated 2026-01-26

    Blood glucose management in type 1 diabetes (T1D) remains a challenge, with only \~30% of adults within the recommended consensus guidelines. Novel drugs like glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have emerged as promising add-ons to insulin in T1D. This application has been designed to test in a prospective study whether adding a new medicine called tirzepatide (GIP/GLP-1RA) to the usual insulin therapy would make a difference for people with T1D in terms of better glucose control.

  3. NCT06046833

    Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes

    Recruiting · Not Applicable · registry updated 2026-08-03

    A pilot study to evaluate and compare glucose metrics using a real-time continuous glucose monitor (FreeStyle Libre 3 sensor) between patients with diabetes and gastroparesis and those with diabetes without gastroparesis.

  4. NCT07808151

    Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

    Not Yet Recruiting · Phase 2 · registry updated 2026-09-08

    The goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer in adults. This type of cancer can be removed with surgery and has not spread to other parts of the body. Both medicines work by helping the immune system fight cancer. The main questions this study wants to answer: How well do the medicines destroy the cancer before surgery? What side effects do participants have when taking the medicines? Researchers will compare two groups to see which treatment schedule works better and is safer. Both groups get pembrolizumab. One group gets one dose of porustobart (Day 1 only), and the other group gets two doses (Day 1 and Day 22). Participants will: Complete certain tests and procedures to make sure they are eligible Get the medicines through a vein on Day 1 and Day 22 then have surgery 6-9 weeks after starting treatment Return for checkups and tests every 6 months for up to 3 years after surgery

  5. NCT05546138

    Characterization and Prediction of Early Onset Diabetic Peripheral Neuropathy

    Recruiting · Not specified · registry updated 2024-06-28

    Predicting early onset neuropathy in people with type 1 diabetes

  6. NCT06474598

    An Adaptive Design Study of MTX228

    Recruiting · Phase 2 · registry updated 2026-04-13

    MTX228 has been identified as a medication that might allow the re-growth of insulin producing beta cells in people with Type 1 Diabetes. Promoting the re-growth of lost beta cells would be beneficial to people with Type 1 Diabetes because it would allow them to take less insulin by injection and would improve their overall blood sugar control while reducing the risk and rate of low blood sugars. This open-label dose selection study aims to determine the optimal dose ofMTX228 for use in a future phase IIb study. The purpose is to investigate the relative effectiveness of different doses of MTX228 and to select the most effective dose for further investigation in a phase 2b study.

  7. NCT06496412

    Safety and Efficacy of Fecal Microbiota Transplantation on Cognitive Function in T1DM

    Recruiting · Not Applicable · registry updated 2024-07-11

    This study is a prospective, single-center, parallel-design,1:1 randomized controlled trial with triple blinding. It aims to investigate the effects of fecal microbiota transplantation (FMT) on cognitive function in patients with long-term type 1 diabetes (T1D), as well as its effects on other complications, glycemic control, insulin dosage, insulin resistance, peripheral blood immune cells, serum metabolites, and safety. This study is divided into two phases for recruiting participants. The first phase recruits 10 individuals (experimental group: 5, control group: 5), while the second phase recruits 30 individuals (experimental group: 15, control group: 15).The main research objectives are as follows: 1. To observe the difference in cognitive function between the FMT group and the placebo group, with the indicators including cognitive scale scores, changes in brain MRI imaging indicators and brain age at week 24 compared to baseline. 2....

  8. NCT05286892

    Diabetes Learning in Virtual Environments Just in Time for Community Reentry

    Recruiting · Not Applicable · registry updated 2025-07-28

    The proposed study will use a randomized clinical trial design with non-equivalent control group and longitudinal design to evaluate the feasibility, acceptability, and preliminary effects of the Diabetes LIVE JustICE application. The design will incorporate repeated measures at 0, 6, and 12 weeks. Outcome variables will include recruitment assessments, participation, engagement, user experience, and measures proximally related to behavior change - e.g., diabetes knowledge, diabetes-related distress, diabetes self-care, and social support and clinical outcomes -e.g., glycemic control. Focus group interviewing will be conducted to evaluate acceptability among intervention group participants.